Barclays’s Zymergen Inc. Common Stock ZY Stock Holding History

Barclays’s Portfolio ZY Stock Details ZY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-16,555	Closed	-$47K	–	5459
2022 Q1	$47K	Buy	+16,555	New	+$70.3K	﹤0.01%	4144

Other funds holding ZY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

TVPI

True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

DCI

Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TSV

Two Sigma Ventures New York $9.61M AUM 58.41% 1-Year Est. Return

Barclays's ZY Position: Q2 2022 in Review

Barclays sold out of Zymergen Inc. Common Stock (ZY) in Q2 2022, closing a stake of 16,555 shares — an estimated $47K sold.

Barclays first reported a position in ZY in Q1 2022 and held it in 1 quarter. The position peaked at $47K in Q1 2022. 81 funds tracked by Wall St. Rank hold ZY as of Q2 2022.

Barclays reported no remaining Zymergen Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Barclays sold 16,555 Zymergen Inc. Common Stock shares in Q2 2022, an estimated $47K.
Barclays first reported a position in Zymergen Inc. Common Stock in Q1 2022 and held it in 1 quarter.
Barclays's Zymergen Inc. Common Stock position peaked at $47K in Q1 2022.
81 funds tracked by Wall St. Rank held Zymergen Inc. Common Stock as of Q2 2022.

Based on Barclays's 13F filing for Q2 2022, filed 12 Aug 2022.